SELLAS Life Sciences Group, Inc. (SLS) stock
SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$19.15+11.68 (+156.36%)
Close on Nov 17, 2026Market cap $3.87BP/E –Yield –
SELLAS Life Sciences gross margin
Gross margin is gross profit as a percentage of revenue.
SELLAS Life Sciences's gross margin for the twelve months ending Dec 31, 2022 was 90.0%. For fiscal 2022 it was 90.0%, against 97.4% the year before. The highest annual figure on record is 100.0% in fiscal 2020.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 90.0% | −7.4 |
| FY2021 | Dec 31, 2021 | 97.4% | −2.6 |
| FY2020 | Dec 31, 2020 | 100.0% | +15.1 |
| FY2014 | Dec 31, 2014 | 84.9% | +5.9 |
| FY2013 | Dec 31, 2013 | 79.1% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2022 | Mar 31, 2022 | 90.0% | – |
| Q2 FY2021 | Jun 30, 2021 | 94.7% | – |
| Q1 FY2021 | Mar 31, 2021 | 98.2% | – |
| Q4 FY2020 | Dec 31, 2020 | 100.0% | – |
See a number that looks wrong?